JP2012521201A5 - - Google Patents

Download PDF

Info

Publication number
JP2012521201A5
JP2012521201A5 JP2012501126A JP2012501126A JP2012521201A5 JP 2012521201 A5 JP2012521201 A5 JP 2012521201A5 JP 2012501126 A JP2012501126 A JP 2012501126A JP 2012501126 A JP2012501126 A JP 2012501126A JP 2012521201 A5 JP2012521201 A5 JP 2012521201A5
Authority
JP
Japan
Prior art keywords
arginase
peg
pharmaceutical composition
genetically modified
bacillus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012501126A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012521201A (ja
JP5746137B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2010/071357 external-priority patent/WO2010124547A1/en
Publication of JP2012521201A publication Critical patent/JP2012521201A/ja
Publication of JP2012521201A5 publication Critical patent/JP2012521201A5/ja
Application granted granted Critical
Publication of JP5746137B2 publication Critical patent/JP5746137B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012501126A 2009-03-26 2010-03-26 アルギナーゼの部位指定的ペグ化並びにその抗がん剤及び抗ウイルス剤としての使用 Active JP5746137B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16386309P 2009-03-26 2009-03-26
US61/163,863 2009-03-26
PCT/CN2010/071357 WO2010124547A1 (en) 2009-03-26 2010-03-26 Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents

Publications (3)

Publication Number Publication Date
JP2012521201A JP2012521201A (ja) 2012-09-13
JP2012521201A5 true JP2012521201A5 (cg-RX-API-DMAC7.html) 2013-05-09
JP5746137B2 JP5746137B2 (ja) 2015-07-08

Family

ID=42784510

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012501126A Active JP5746137B2 (ja) 2009-03-26 2010-03-26 アルギナーゼの部位指定的ペグ化並びにその抗がん剤及び抗ウイルス剤としての使用

Country Status (7)

Country Link
US (1) US8507245B2 (cg-RX-API-DMAC7.html)
EP (1) EP2411040B1 (cg-RX-API-DMAC7.html)
JP (1) JP5746137B2 (cg-RX-API-DMAC7.html)
CN (1) CN102481345B (cg-RX-API-DMAC7.html)
AU (1) AU2010242422B2 (cg-RX-API-DMAC7.html)
CA (1) CA2756442C (cg-RX-API-DMAC7.html)
WO (1) WO2010124547A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9382525B2 (en) * 2009-03-26 2016-07-05 The Hong Kong Polytechnic University Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents
WO2011008495A2 (en) * 2009-06-29 2011-01-20 The Board Of Regents Of The University Of Texas System Arginase formulations and methods
US9682132B2 (en) 2010-01-26 2017-06-20 Banyan Biomarkers, Inc Compositions and methods relating to argininosucccinate synthetase
WO2012085793A1 (en) * 2010-12-21 2012-06-28 Ning Man Cheng Use of pegylated recombinant human arginase for treatment of leukemia
CN103184209B (zh) * 2011-12-27 2015-09-16 拜奥生物科技(上海)有限公司 人精氨酸酶和聚乙二醇化人精氨酸酶及其应用
US9011845B2 (en) 2012-06-26 2015-04-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for treatment of inflammatory and infectious viral diseases
WO2014003850A2 (en) 2012-06-26 2014-01-03 Timothy Paul Foster Methods for treatment of ocular diseases
GB2535937B (en) * 2014-04-29 2017-05-31 Bio-Cancer Treat Int Ltd Arginase I for treating rheumatoid arthritis
CN105112391B (zh) * 2015-09-22 2018-07-06 浙江道尔生物科技有限公司 一种人源精氨酸酶突变体及其制备方法和用途
CN106692961B (zh) * 2015-11-17 2020-12-11 长春市福迪奥美科技有限公司 精氨酸酶组合物、精氨酸酶激活剂及其应用
CN106434710A (zh) * 2016-10-14 2017-02-22 江南大学 一种耐热精氨酸酶的基因表达序列和应用
CN108265044B (zh) * 2016-12-31 2021-05-11 江苏众红生物工程创药研究院有限公司 聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用
TW201910513A (zh) * 2017-08-16 2019-03-16 香港商鎧耀波麗堂(香港)有限公司 胺基酸耗竭治療的組合物及方法
CN112513099A (zh) * 2018-05-31 2021-03-16 香港理工大学 用于癌症、肥胖症、代谢紊乱和相关并发症及合并症的精氨酸耗竭剂的组合物和应用
KR20210095141A (ko) 2018-10-19 2021-07-30 에어레이즈, 인크. 지에이엠티 결핍 치료를 위한 아르기닌 결핍 요법
CN109793917B (zh) * 2019-02-11 2020-10-09 海南建科药业有限公司 一种预防结直肠手术后吻合口瘘的凝胶的制备方法
KR20220082813A (ko) 2019-08-30 2022-06-17 아이글레아 바이오테라퓨틱스, 인크. 인간 재조합 아르기나아제 1의 제조 방법 및 이의 사용
WO2021110071A1 (en) * 2019-12-02 2021-06-10 The Hong Kong Polytechnic University Methods for inducing intermittent fasting and modulating autophagy
CA3180529A1 (en) * 2020-04-17 2021-10-21 Bio-Cancer Treatment International Limited Methods of treating viral infections using arginase
CN115843267A (zh) * 2020-05-14 2023-03-24 克云生物科技股份公司 呼吸道病毒感染的治疗
WO2022063178A1 (en) * 2020-09-23 2022-03-31 The Hong Kong Polytechnic University Fluorescent biosensor for rapid determination of l-arginine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
EP1499342A2 (en) * 2002-01-25 2005-01-26 Cancer Treatments International Therapeutic composition for treatment of cancer by arginine depletion
EP1908478B1 (en) 2002-06-20 2010-03-24 Bio-Cancer Treatment International Limited Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation
HK1053577A2 (en) * 2002-06-20 2003-10-10 Bio-Cancer Treatment International Limited Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation
JP2006501820A (ja) * 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン 修飾glp−1受容体アゴニストおよびそれらの薬理学的使用法
CN1745847A (zh) 2004-09-08 2006-03-15 康达医药科技有限公司 用精氨酸酶治疗肝炎的药物组合物和方法
WO2006058486A1 (en) 2004-12-03 2006-06-08 Bio-Cancer Treatment International Limited Use of arginase in combination with 5fu and other compounds for treatment of human malignancies
WO2011008495A2 (en) * 2009-06-29 2011-01-20 The Board Of Regents Of The University Of Texas System Arginase formulations and methods

Similar Documents

Publication Publication Date Title
JP2012521201A5 (cg-RX-API-DMAC7.html)
Varkouhi et al. Endosomal escape pathways for delivery of biologicals
ES2741524T3 (es) Profármaco polimérico con un enlazador autoinmolador
JP5600846B2 (ja) キトサン基材高分子接合体及びその製造方法
CN103402545B (zh) 疏水性经修饰肽及其在肝特异性靶向中的用途
JP2012522802A5 (cg-RX-API-DMAC7.html)
JP2010505831A5 (cg-RX-API-DMAC7.html)
JP4805911B2 (ja) Hiv侵入阻害剤のポリマー系組成物及び複合体
JP2012176978A5 (cg-RX-API-DMAC7.html)
JP2008525423A5 (cg-RX-API-DMAC7.html)
JP2009292810A5 (cg-RX-API-DMAC7.html)
JP2013172743A5 (cg-RX-API-DMAC7.html)
JP2015529678A5 (cg-RX-API-DMAC7.html)
EP3638284B1 (en) Cyclic peptides for protection against respiratory syncytial virus
WO2017198124A1 (zh) 多臂的聚合靶向抗癌偶联物
Cruz et al. A comparative study of different presentation strategies for an HIV peptide immunogen
ES2528109T3 (es) Compuestos inmunogénicos que comprenden péptido gp41 de VIH acoplado a proteína portadora CRM197
WO2010134305A1 (ja) Hiv立体構造認識抗体誘導ペプチド抗原、及びその合成方法
US11957762B2 (en) Immune tolerant and non-immune tolerant elastin-like recombinant peptides and methods of use
JP2014525939A5 (cg-RX-API-DMAC7.html)
HRP20140886T1 (hr) MUTANTI CyaA POLIPEPTIDI I POLIPEPTIDNI DERIVATI PRIKLADNI ZA DOPREMANJE IMUNOGENIÄŚNIH MOLEKULA U STANICU
US20080026077A1 (en) Methods and compositions of gene delivery agents for systemic and local therapy
KR102668425B1 (ko) 분해성 폴리에틸렌글리콜 결합체
JP2012521207A5 (cg-RX-API-DMAC7.html)
CN101289500A (zh) 病毒感染的长效融合肽抑制剂